Clinical implications of a molecular genetic classification of monogenic β-cell diabetes
The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
Monogenic diabetes resulting from mutations that primarily reduce beta-cell function accounts for 1-2% of diabetes cases, although it is often misdiagnosed as either type 1 or type 2 diabetes. Knowledge of the genetic etiology of diabetes enables more-appropriate treatment, better prediction of disease progression, screening of family members and genetic counseling. We propose that the old clinical classifications of maturity-onset diabetes of the young and neonatal diabetes are obsolete and that specific genetic etiologies should be sought in four broad clinical situations because of their specific treatment implications. Firstly, diabetes diagnosed before 6 months of age frequently results from mutation of genes that encode Kir6.2 (ATP-sensitive inward rectifier potassium channel) or sulfonylurea receptor 1 subunits of an ATP-sensitive potassium channel, and improved glycemic control can be achieved by treatment with high-dose sulfonylureas rather than insulin. Secondly, patients with stable, mild fasting hyperglycemia detected particularly when they are young could have a glucokinase mutation and might not require specific treatment. Thirdly, individuals with familial, young-onset diabetes that does not fit with either type 1 or type 2 diabetes might have mutations in the transcription factors HNF-1alpha (hepatocyte nuclear factor 1-alpha) or HNF-4alpha, and can be treated with low-dose sulfonylureas. Finally, extrapancreatic features, such as renal disease (caused by muta…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, an exception is the mutational analyses established for classification of diabetes in the neonate (381-384) as well as in young individuals with a dominant family history of diabetes, often referred to as maturityonset diabetes of the young (MODY) (384,385) (Table 8).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [383]
In the citing paper
“Infants with neonatal diabetes due to a mutation in the KCNJ11 (potassium inwardly-rectifying channel, subfamily J, member 11; also known as KIR6.2) gene may be treated with sulfonylurea rather than with insulin (258,259).”
From Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (2011) · cites this paper as [258]
In the citing paper
“Genetic markers are currently of limited clinical value in evaluating and managing patients with diabetes; however, mutational analysis is rapidly emerging for classifying diabetes in the neonate (258-260) and in young patients with a dominant family history of diabetes, often referred to as “maturityonset diabetes of the young” (MODY) (261).”
From Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (2011) · cites this paper as [258]
Citations
Cites
Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., Whitesell, L., Kelly, T. E., Saulsbury, F. T., Chance, P. F., & Ochs, H. D. (2001) · Nature Genetics · doi:10.1038/83713 · Cited by 3,402
Goto, Y.-I., Nonaka, I., & Horai, S. (1990) · Nature · doi:10.1038/348651a0 · Cited by 2,070
Wildin, R. S., Ramsdell, F., Peake, J., Faravelli, F., Casanova, J.-L., Buist, N., Levy-Lahad, E., Mazzella, M., Goulet, O., Perroni, L., et al. (2001) · Nature Genetics · doi:10.1038/83707 · Cited by 1,922
Gloyn, A. L., Pearson, E. R., Antcliff, J. F., Proks, P., Bruining, G. J., Slingerland, A. S., Howard, N., Srinivasan, S., Silva, J. M. C. L., Molnes, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032922 · Cited by 1,137
Self-citationSwitching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061759 · Cited by 988
Self-citationChatila, T. A., Blaeser, F., Ho, N., Lederman, H. M., Voulgaropoulos, C., Helms, C., & Bowcock, A. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11679 · Cited by 940
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 1×
“Currently, insulin remains the most common treatment during pregnancy for this patient group, but further studies are required to validate the safety and efficacy of sulfonylureas such as glibenclamide (also known as glyburide) that have least permeability through the placenta and have been used in gestational diabetes”
BackgroundEarly-onset type-ll diabetes mellitus (MODY4) linked to IPF1
Staffers, D. A., Ferrer, J., Clarke, W. L., & Habener, J. F. (1997) · Nature Genetics · doi:10.1038/ng1097-138 · Cited by 882
Delépine, M., Nicolino, M., Barrett, T., Golamaully, M., Mark Lathrop, G., & Julier, C. (2000) · Nature Genetics · doi:10.1038/78085 · Cited by 813
Froguel, P., Zouali, H., Vionnet, N., Velho, G., Vaxillaire, M., Sun, F., Lesage, S., Stoffel, M., Takeda, J., Passa, P., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303113281005 · Cited by 735 · cited 1×
“Most of those without diabetes have impaired fasting glucose levels”
Background
Research works printed but not linked: 1
- Pearson E et al. (2003) HDL-cholesterol: differentiating between HNF-1α MODY and type 2 diabetes [abstract]. Diabet Med 20 (Suppl 2): S1–S33
Cited by
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.161596 · Cited by 1,360
“2) gene may be treated with sulfonylurea rather than with insulin (258,259).”
Diabetes mellitus: The epidemic of the century
Kharroubi, A. T. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.850 · Cited by 1,229
The genetic architecture of type 2 diabetes
Fuchsberger, C., Flannick, J., Teslovich, T. M., Mahajan, A., Agarwala, V., Gaulton, K. J., Ma, C., Fontanillas, P., Moutsianas, L., McCarthy, D. J., et al. (2016) · Nature · doi:10.1038/nature18642 · Cited by 1,051
Self-citationRare Variants of IFIH1 , a Gene Implicated in Antiviral Responses, Protect Against Type 1 Diabetes
Nejentsev, S., Walker, N., Riches, D., Egholm, M., & Todd, J. A. (2009) · Science · doi:10.1126/science.1167728 · Cited by 958
Genomics, type 2 diabetes, and obesity
McCarthy, M. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0906948 · Cited by 938
Type 2 diabetes across generations: from pathophysiology to prevention and management
Nolan, C. J., Damm, P., & Prentki, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60614-4 · Cited by 923
Diabetes Mellitus and the β Cell: The Last Ten Years
Ashcroft, F. M., & Rorsman, P. (2012) · Cell · doi:10.1016/j.cell.2012.02.010 · Cited by 902
Differentiation of diabetes by pathophysiology, natural history, and prognosis
Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L., Groop, P.-H., Handelsman, Y., Insel, R. A., Mathieu, C., et al. (2017) · Diabetes · doi:10.2337/db16-0806 · Cited by 823
“Maturity-onset diabetes of the young (MODY) is a monogenic disease and has a high h2 of ;50 (20).”
BackgroundInfluentialMaturity-onset diabetes of the young (MODY): how many cases are we missing?
Shields, B. M., Hicks, S., Shepherd, M. H., Colclough, K., Hattersley, A. T., & Ellard, S. (2010) · Diabetologia · doi:10.1007/s00125-010-1799-4 · Cited by 725
“Mutations in the HNF1B, NEUROD1, PDX1 and INS genes are rare causes of MODY [5].”
BackgroundSelf-citationSacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Diabetes Care · doi:10.2337/dc11-9998 · Cited by 718
“2) gene may be treated with sulfonylurea rather than with insulin (258,259).”
Mayer-Davis, E. J., Kahkoska, A. R., Jefferies, C., Dabelea, D., Balde, N., Gong, C. X., Aschner, P., & Craig, M. E. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12773 · Cited by 682
“extended genetic testing in other diabetic family members, whose diabetes may eventually be reclassified.(142)”
The many faces of diabetes: a disease with increasing heterogeneity
Tuomi, T., Santoro, N., Caprio, S., Cai, M., Weng, J., & Groop, L. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62219-9 · Cited by 652
The clinical utility of C‐peptide measurement in the care of patients with diabetes
Jones, A. G., & Hattersley, A. T. (2013) · Diabetic Medicine · doi:10.1111/dme.12159 · Cited by 628
Self-citationDefinition, epidemiology and classification of diabetes in children and adolescents
Craig, M. E., Hattersley, A., & Donaghue, K. C. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2009.00568.x · Cited by 461
“(MODY) was originally described as a disorder with the following characteristics: onset before 25 years of age, autosomal dominant inheritance, nonketotic diabetes mellitus (22; 57; 61).”
BackgroundSelf-citationGenetics of Type 2 Diabetes—Pitfalls and Possibilities
Prasad, R., & Groop, L. (2015) · Genes · doi:10.3390/genes6010087 · Cited by 458
“MODY shows extreme allelic heterogeneity meaning that most MODY mutations are unique; to date, there are more than 200 mutations described in the GCK (MODY2) and HNF1A (MODY3) genes [28,29].”
BackgroundMahajan, A., Wessel, J., Willems, S. M., Zhao, W., Robertson, N. R., Chu, A. Y., Gan, W., Kitajima, H., Taliun, D., Rayner, N. W., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0084-1 · Cited by 442
“For example, rare coding mutations at HNF1A and HNF4A are causal for monogenic, early-onset forms of diabetes 24 , and at TM6SF2 and PNPLA3 the associated coding variants are implicated in the development of non-alcoholic fatty liver disease (NAFLD) 25,26 .”
Paulmann, N., Grohmann, M., Voigt, J.-P., Bert, B., Vowinckel, J., Bader, M., Skelin, M., Jevšek, M., Fink, H., Rupnik, M., et al. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000229 · Cited by 404
“is a possible candidate gene for this metabolic disorder in humans, especially as a genetic diagnosis in at least 11% of European and as many as 70%–80% of Asian families with a diagnosis of MODY cannot be made, indicating that additional MODY-related genes need to be identified”
BackgroundType I interferonopathies: a novel set of inborn errors of immunity
Crow, Y. J. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06220.x · Cited by 404
Pihoker, C., Gilliam, L. K., Ellard, S., Dabelea, D., Davis, C., Dolan, L. M., Greenbaum, C. J., Imperatore, G., Lawrence, J. M., Marcovina, S. M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1279 · Cited by 397
“These patients do not require any pharmacological treatment and do not develop diabetes complications (2, 31).”
BackgroundSelf-citationMolecular Physiology of Mammalian Glucokinase
Iynedjian, P. B. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8322-9 · Cited by 365
Definition, epidemiology, and classification of diabetes in children and adolescents
Craig, M. E., Jefferies, C., Dabelea, D., Balde, N., Seth, A., & Donaghue, K. C. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12186 · Cited by 366
“Making a specific molecular diagnosis helps predict the expected clinical course of the disease, guide the most appropriate management for an individual, and has important implications for family members, enabling genetic counseling and extended genetic testing in other diabetic family members, whose diabetes may even…”
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
“2) gene may be treated with sulfonylurea rather than with insulin (258,259).”
Hattersley, A. T., Greeley, S. A. W., Polak, M., Rubio-Cabezas, O., Njølstad, P. R., Mlynarski, W., Castano, L., Carlsson, A., Raile, K., Chi, D. V., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12772 · Cited by 319
“Over the last few years, however, a number of forms of monogenic diabetes clinically and genetically different from MODY have been identified.(5) Patients may harbor dominant mutations arising de novo; in such cases, family history suggesting a monogenic condition is lacking.”
Self-citationPrecision diabetes: learning from monogenic diabetes
Hattersley, A. T., & Patel, K. A. (2017) · Diabetologia · doi:10.1007/s00125-017-4226-2 · Cited by 306
“The recognition of MODY has been slow despite MODY being relatively common, the technology for genetic diagnosis being available in most countries and clear treatment recommendations having been defined once a diagnosis is made, both outside and during pregnancy [6, 24].”
BackgroundSelf-citationChakera, A. J., Steele, A. M., Gloyn, A. L., Shepherd, M. H., Shields, B., Ellard, S., & Hattersley, A. T. (2015) · Diabetes Care · doi:10.2337/dc14-2769 · Cited by 289
“GCK-MODY and HNF1A-MODY are the most common causes of MODY (21,22,24).”
BackgroundSelf-citationHNF1B Mutations Associate with Hypomagnesemia and Renal Magnesium Wasting
Adalat, S., Woolf, A. S., Johnstone, K. A., Wirsing, A., Harries, L. W., Long, D. A., Hennekam, R. C., Ledermann, S. E., Rees, L., van't Hoff, W., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008060633 · Cited by 277
Self-citationEndoplasmic reticulum stress and eIF2α phosphorylation: The Achilles heel of pancreatic β cells
Cnop, M., Toivonen, S., Igoillo-Esteve, M., & Salpea, P. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.001 · Cited by 268
The diagnosis and management of monogenic diabetes in children and adolescents
Hattersley, A., Bruining, J., Shield, J., Njolstad, P., & Donaghue, K. C. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2009.00571.x · Cited by 255
Self-citationShepherd, M., Shields, B., Hammersley, S., Hudson, M., McDonald, T. J., Colclough, K., Oram, R. A., Knight, B., Hyde, C., Cox, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0645 · Cited by 236
“Making the correct diagnosis of monogenic diabetes is vitally important because the management of the most common subtypes (GCK, HNF1A, and HNF4A maturity-onset diabetes of the young [MODY]) is markedly different from that for type 1 diabetes (9,10).”
BackgroundSelf-citationMaturity-onset diabetes of the young (MODY): current perspectives on diagnosis and treatment
Urakami, T. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s179793 · Cited by 206
“76 These patients may require intensive insulin treatment to control hyperglycemia.”
BackgroundGreeley, S. A. W., Polak, M., Njølstad, P. R., Barbetti, F., Williams, R., Castano, L., Raile, K., Chi, D. V., Habeb, A., Hattersley, A. T., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13426 · Cited by 211
“They develop severe but nonketotic hyperglycemia very early, usually during the first week of life.27,30 • Despite the severity of the initial presentation, the insulin dose can be tapered quickly so that most infants do not require any treatment by a median age of 12–14 weeks and the rate of remission is close to 100…”
BackgroundInfluentialSelf-citationWhole-Exome Sequencing and High Throughput Genotyping Identified KCNJ11 as the Thirteenth MODY Gene
Bonnefond, A., Philippe, J., Durand, E., Dechaume, A., Huyvaert, M., Montagne, L., Marre, M., Balkau, B., Fajardy, I., Vambergue, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037423 · Cited by 204
“KCNJ11 gene screening is currently indicated by guidelines in all patients who present with diabetes diagnosed before 6–12 months of age [6,19,20].”
BackgroundThe diagnosis and management of monogenic diabetes in children and adolescents
Rubio-Cabezas, O., Hattersley, A. T., Njølstad, P. R., Mlynarski, W., Ellard, S., White, N., Chi, D. V., & Craig, M. E. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12192 · Cited by 196
“Over the last few years, however, a number of forms of monogenic diabetes clinically and genetically different from MODY have been identified (6).”
Self-citationMonogenic diabetes: a gateway to precision medicine in diabetes
Zhang, H., Colclough, K., Gloyn, A. L., & Pollin, T. I. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142244 · Cited by 188
“1172/JCI142244 most MODY cases and the increased frequency of pediatric T2D due to increased childhood overweight and obesity prevalence, it has been suggested that this term be abandoned in favor of terms describing the etiology of the type of diabetes, such as transcription factor diabetes for MODY caused by mutatio…”
BackgroundSchober, E., Rami, B., Grabert, M., Thon, A., Kapellen, T., Reinehr, T., & Holl, R. W. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02720.x · Cited by 182
Nkonge, K. M., Nkonge, D. K., & Nkonge, T. N. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-020-00112-5 · Cited by 178
Treatment options for MODY patients: a systematic review of literature
Delvecchio, M., Pastore, C., & Giordano, P. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00864-4 · Cited by 172
Genetics of diabetes – Are we missing the genes or the disease?
Groop, L., & Pociot, F. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.04.002 · Cited by 187
“MODY shows extreme allelic heterogeneity meaning that most MODY mutations are unique; to date, there are more than 200 mutations described in the GCK (MODY2) and HNF1A (MODY3) genes (Murphy et al., 2008).”
BackgroundInsulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes
Balboa, D., Saarimäki‐Vire, J., Borshagovski, D., Survila, M., Lindholm, P., Galli, E., Eurola, S., Ustinov, J., Grym, H., Huopio, H., et al. (2018) · eLife · doi:10.7554/elife.38519 · Cited by 152
“63 Permanent neonatal diabetes mellitus (PNDM) is caused by mutations in genes 64 controlling beta-cell development or functionality, and is usually diagnosed before 6 months of 65 age (Greeley et al., 2011; Murphy et al., 2008).”
BackgroundImmunologic endocrine disorders
Michels, A. W., & Eisenbarth, G. S. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.053 · Cited by 176
“Nat Clin Pract Endocrinol Metab 2008 April;4(4):200–13.”
BackgroundInfluentialSacks, D. B., Arnold, M. A., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad080 · Cited by 200
“2) gene may be treated with sulfonylurea rather than with insulin (258,259).”
Minimal incidence of neonatal/infancy onset diabetes in Italy is 1:90,000 live births
The Early Diabetes Study Group of ISPED, Iafusco, D., Massa, O., Pasquino, B., Colombo, C., Iughetti, L., Bizzarri, C., Mammì, C., Presti, D. L., Suprani, T., et al. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0331-8 · Cited by 145
The emerging genetics of type 2 diabetes
Bonnefond, A., Froguel, P., & Vaxillaire, M. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.06.004 · Cited by 174
Common and rare forms of diabetes mellitus: towards a continuum of diabetes subtypes
Flannick, J. A., Johansson, S., & Njølstad, P. R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.50 · Cited by 165
Servitja, J., Pignatelli, M., Maestro, M. Á., Cardalda, C. A., Boj, S. F., Lozano, J. J., Blanco, E., Lafuente, A., McCarthy, M. I., Sumoy, L., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01389-08 · Cited by 156
“Human genetics has provided an important source of information by uncovering transcription factor genes that are mutated in -cell-deficient forms of diabetes (40, 58, 71, 73).”
BackgroundHeterozygous RFX6 protein truncating variants are associated with MODY with reduced penetrance
Patel, K., Kettunen, J. L. T., Laakso, M., Stančáková, A., Laver, T. W., Colclough, K., Johnson, M. B., Abramowicz, M., Groop, L., Miettinen, P. J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00895-9 · Cited by 149
Self-citationFlannick, J., Beer, N. L., Bick, A. G., Agarwala, V., Molnes, J., Gupta, N., Burtt, N. P., Florez, J. C., Meigs, J. B., Taylor, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2794 · Cited by 136
Naylor, R. N., John, P. M., Winn, A. N., Carmody, D., Greeley, S. A. W., Philipson, L. H., Bell, G. I., & Huang, E. S. (2013) · Diabetes Care · doi:10.2337/dc13-0410 · Cited by 149
“Molecular diagnosis of GCK-MODY allows pharmacologic therapy to be discontinued and decreases the needed frequency of medical surveillance (9,10).”
BackgroundSansbury, F. H., Flanagan, S. E., Houghton, J., Shen, F. L. S., Senani, A. A., Habeb, A. M., Abdullah, M. A., Kariminejad, A., Ellard, S., & Hattersley, A. T. (2012) · Diabetologia · doi:10.1007/s00125-012-2595-0 · Cited by 153
“TNDM is most commonly due to an imprinting disorder at chromosome 6q24, and also to mutations in KCNJ11 or ABCC8 [9].”
BackgroundResultInfluentialSelf-citationMonogenic Diabetes: What It Teaches Us on the Common Forms of Type 1 and Type 2 Diabetes
Yang, Y., & Chan, L. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1116 · Cited by 152
Learning From Molecular Genetics
McCarthy, M. I., & Hattersley, A. T. (2008) · Diabetes · doi:10.2337/db08-0343 · Cited by 147
“2); many of these genetically defined subgroups can, at least in part, be separated by their clinical features (22,23).”
BackgroundSelf-citationTimpson, N. J., Lindgren, C. M., Weedon, M. N., Randall, J. C., Ouwehand, W. H., Strachan, D. P., Rayner, N. W., Walker, M., Hitman, G. A., Doney, A. S. F., et al. (2008) · Diabetes · doi:10.2337/db08-0906 · Cited by 129
“Indeed, a molecular classification of diabetes subtype is already a reality for low-frequency high-penetrance DNA variants responsible for monogenic and syndromic forms of diabetes, such as maturity-onset diabetes of the young and mitochondrial diabetes (9).”
BackgroundSelf-citationBonnefond, A., Durand, E., Sand, O., Graeve, F. D., Gallina, S., Busiah, K., Lobbens, S., Simon, A., Bellanné‐Chantelot, C., Létourneau, L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013630 · Cited by 126
“Indeed, although the majority of TNDM cases have an abnormality in chromosome 6q24 and the other most frequent causes of NDM are missense mutations in the pancreatic b-cell KATP channel genes KCNJ11 and ABCC8, and in the preproinsulin gene, NDM has been linked to numerous other genetic causes including point mutations…”
BackgroundInfluentialAbsence of BiP Co-chaperone DNAJC3 Causes Diabetes Mellitus and Multisystemic Neurodegeneration
Synofzik, M., Haack, T. B., Kopajtich, R., Gorza, M., Rapaport, D., Greiner, M., Schönfeld, C., Freiberg, C., Schorr, S., Holl, R. W., et al. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.10.013 · Cited by 118
Thanabalasingham, G., Shah, N., Vaxillaire, M., Hansen, T. F., Tuomilehto, J., Gašperíková, D., Szopa, M., Tjora, E., James, T. J., Kokko, P., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2261-y · Cited by 128
“Meta-analysis across all samples concurred with this result (z value −21.8, p 18 ].”
ResultInfluentialRubio‐Cabezas, O., & Ellard, S. (2013) · Hormone Research in Paediatrics · doi:10.1159/000354219 · Cited by 117
Self-citationCarlsson, A., Shepherd, M., Ellard, S., Weedon, M., Lernmark, Å., Forsander, G., Colclough, K., Brahimi, Q., Valtonen-Andre, C., Ivarsson, S. A., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0747 · Cited by 111
“The most common subtypes of MODY areglucokinase(GCK)MODY,whichneeds no treatment, and hepatocyte nuclear factor-1a (HNF1A) MODY and HNF4A MODY, which are both optimally treated with low-dose sulphonylureaswhenpharmaceutical therapy is needed (2,9).”
BackgroundSelf-citationAquilante, C. L. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.154 · Cited by 137
Exome Sequencing and Genetic Testing for MODY
Johansson, S., Irgens, H. U., Chudasama, K., Molnes, J., Aerts, J. A., Roque, F. S., Jonassen, I., Levy, S., Lima, K., Knappskog, P. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038050 · Cited by 117
“MODY (maturity-onset diabetes of the young) is a heterogeneous group of diabetes caused by single gene defects in at least ten genes affecting pancreas development and beta-cell function [1,2,3].”
Backgroundstudy, F. T. U., Shepherd, M. H., Shields, B. M., Hudson, M., Pearson, E. R., Hyde, C., Ellard, S., Hattersley, A. T., & Patel, K. (2018) · Diabetologia · doi:10.1007/s00125-018-4728-6 · Cited by 122
Self-citationEisenbarth, G. S. (2010) · Diabetes · doi:10.2337/db09-1855 · Cited by 118
The genetics of drug efficacy: opportunities and challenges
Nelson, M. R., Johnson, T., Warren, L. L., Hughes, A. R., Chissoe, S. L., Xu, C., & Waterworth, D. M. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.12 · Cited by 116
Update on clinical screening of maturity-onset diabetes of the young (MODY)
Peixoto-Barbosa, R., Reis, A. F., & Giuffrida, F. M. A. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00557-9 · Cited by 116
“Patients present some degree of hepatic insulin resistance, explaining why approximately half of them do not respond to sulfonylureas, needing early insulin therapy [7, 53].”
BackgroundSaarimäki‐Vire, J., Balboa, D., Russell, M. A., Saarikettu, J., Kinnunen, M., Keskitalo, S., Malhi, A., Valensisi, C., Andrus, C. R., Eurola, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.055 · Cited by 105
Kleinberger, J. W., Copeland, K. C., Gandica, R., Haymond, M. W., Levitsky, L. L., Linder, B. L., Shuldiner, A. R., Tollefsen, S. E., White, N. H., & Pollin, T. I. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.150 · Cited by 117
Bansal, V., Gassenhuber, J., Phillips, T. C., Oliveira, G., Harbaugh, R., Villarasa, N., Topol, E. J., Seufferlein, T. T. W., & Boehm, B. O. (2017) · BMC Medicine · doi:10.1186/s12916-017-0977-3 · Cited by 111
“To analyze the frequencies of the carriers of such mutations in our cohort, we analyzed genes (HNF1A, HNF4A, HNF1B, INS, ABCC8, and KCNJ11) in which a significant number of missense mutations have previously been reported in MODY, neonatal diabetes mellitus, or early onset diabetes [57].”
MethodDeconstructing Pancreas Developmental BiologyPreprint
Benitez, C. M., Goodyer, W. R., & Kim, S. K. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012401 · Cited by 112
“Additionally, human PDX1 haploinsufficiency is associated with a rare monogenic form of type 2 diabetes called maturity onset diabetes of the young (MODY4), indicating conservation of Pdx1 activity in b-cell identity and function (Stoffers et al. 1997; reviewed by Murphy et al. 2008).”
BackgroundMohan, V., Radha, V., Nguyen, T. T., Stawiski, E. W., Pahuja, K. B., Goldstein, L. D., Tom, J. A., Anjana, R. M., Kong-Beltran, M., Bhangale, T., et al. (2018) · BMC Medical Genetics · doi:10.1186/s12881-018-0528-6 · Cited by 107
“MODY is often misdiagnosed as either type 1 or type 2 diabetes [5].”
BackgroundStem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors
Abdelalim, E. M., & Memon, B. (2020) · Cells · doi:10.3390/cells9020283 · Cited by 115
“Monogenic diabetes (MD), a rare form of the disease, is characterized by genetic mutations in a specific gene involved in pancreatic development and/or beta cell function [2].”
BackgroundNicolino, M. P., Claiborn, K. C., Senée, V., Boland, A., Stoffers, D. A., & Julier, C. (2009) · Diabetes · doi:10.2337/db09-1284 · Cited by 100
“Genes responsible for monogenic neonatal diabetes have been identified by candidate gene studies (PDX1, GCK, HNF1B, KCNJ11, ABCC8), by linkage and positional gene identification in neonatal diabetes syndromes (EIF2AK3, FOXP3, PTF1A, GLIS3), or by linkage and candidate gene study in nonsyndromic neonatal diabetes (INS)…”
BackgroundGenetics and pathophysiology of neonatal diabetes mellitus
Naylor, R. N., Greeley, S. A. W., Bell, G. I., & Philipson, L. H. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00106.x · Cited by 102
Habeb, A. M., Al-Magamsi, M. S., Eid, I. M., Ali, M. I., Hattersley, A. T., Hussain, K., & Ellard, S. (2011) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2011.00828.x · Cited by 98
“So far mutations in a number of genes that can reduce β-cell function, increase β-cell destruction, or reduce pancreatic mass are associated with various forms of PNDM either in isolation or rarely in association with extra-pancreatic features (10).”
BackgroundSelf-citationBacon, S., Kyithar, M. P., Rizvi, S. R., Donnelly, E., McCarthy, A., Burke, M., Colclough, K., Ellard, S., & Byrne, M. M. (2015) · Diabetic Medicine · doi:10.1111/dme.12992 · Cited by 99
Self-citationDiagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T., Karges, B., Kordonouri, O., et al. (2016) · Diabetologie und Stoffwechsel · doi:10.1055/s-0042-111213 · Cited by 91
Precision medicine in type 2 diabetes
Prasad, R. B., & Groop, L. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12859 · Cited by 106
Yorifuji, T., Fujimaru, R., Hosokawa, Y., Tamagawa, N., Shiozaki, M., Aizu, K., Jinno, K., Maruo, Y., Nagasaka, H., Tajima, T., et al. (2011) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2011.00827.x · Cited by 89
“Since the term ‘MODY’ has been questioned by some investigators as inappropriate and obsolete (1), ‘MODY-type diabetes’ is used in this study to describe diabetes with above characteristics.”
BackgroundProinsulin and the Genetics of Diabetes Mellitus
Weiss, M. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.009936 · Cited by 91
Alkorta‐Aranburu, G., Carmody, D., Cheng, Y., Nelakuditi, V., Ma, L., Dickens, J. T., Das, S., Greeley, S. A. W., & del Gaudio, D. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.09.007 · Cited by 96
“Several etiological mechanisms of dysfunction are involved including impairment of pancreatic beta-cell development and/or gene expression, failure of glucose sensing, disruption of insulin synthesis, disorders of ion channels and increased endoplasmic reticulum stress leading to destruction of the beta-cell [3–5].”
BackgroundType 2 Diabetes: Multiple Genes, Multiple Diseases
Udler, M. S. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1169-7 · Cited by 97
Neonatal diabetes mellitus: A model for personalized medicine
Greeley, S. A. W., Tucker, S. E., Naylor, R. N., Bell, G. I., & Philipson, L. H. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.03.004 · Cited by 82
Bellanné‐Chantelot, C., Levy, D. J., Carette, C., Saint‐Martin, C., Riveline, J., Larger, É., Valéro, R., Gautier, J., Reznik, Y., Sola‐Gazagnes, A., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0268 · Cited by 98
“In all patients, other etiologies of diabetes were excluded by the following: 1) the absence of islet cell antibodies or antibodies to glutamic acid decarboxylase; 2) the absence of acanthosis nigricans or polycystic ovary syndrome; and 3) the absence of features consistent with a maternally inherited diabetes and dea…”
BackgroundInfluentialWho should have genetic testing for maturity‐onset diabetes of the young?
Naylor, R. N., & Philipson, L. H. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04049.x · Cited by 93
Maturity onset diabetes of the young and pregnancy
Colom, C., & Corcoy, R. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.05.008 · Cited by 79
Controversies in gestational diabetes
Nolan, C. J. (2010) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2010.10.004 · Cited by 94
Boesgaard, T. W., Průhová, Š., Galijatovic, E. A. A., Cinek, O., Obermannová, B., Lauenborg, J., Damm, P., Bergholdt, R., Pociot, F., Pisinger, C. H., et al. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-42 · Cited by 77
“Heterozygous mutations in INS account for 15 - 20% of cases of PNDM [4,5].”
BackgroundShankar, R. K., Pihoker, C., Dolan, L. M., Standiford, D. A., Badaru, A., Dabelea, D., Rodríguez, B. L., Black, M. H., Imperatore, G., Hattersley, A. T., et al. (2012) · Pediatric Diabetes · doi:10.1111/pedi.12003 · Cited by 78
“Other rare genetic determinants of PNDM include mutations in genes that encode transcription factors such as EIF2AK3 , FOXP3 , IPF-1 , HNF 1B , GLIS 3 and PTF1A (7, 11).”
Self-citationMaturity-Onset Diabetes of the Young (MODY): Making the Right Diagnosis to Optimize Treatment
Amed, S., & Oram, R. A. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.03.002 · Cited by 83
Persistently autoantibody negative (PAN) type 1 diabetes mellitus in children
Hameed, S., Ellard, S., Woodhead, H., Neville, K. A., Walker, J. L., Craig, M. E., Armstrong, T., Yu, L., Eisenbarth, G. S., Hattersley, A. T., et al. (2010) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2010.00681.x · Cited by 73
“We did not sequence GCK because this phenotype (mild, asymptomatic, fasting hyperglycemia from birth) is very unlikely to be confused with type 1 diabetes(2).”
BackgroundSelf-citationGenetics of Monogenic Diabetes: Present Clinical Challenges
Misra, S., & Owen, K. R. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1111-4 · Cited by 83
Permanent diabetes during the first year of life: multiple gene screening in 54 patients
the ISPED Early Diabetes Study Group, Russo, L., Iafusco, D., Brescianini, S., Nocerino, V., Bizzarri, C., Toni, S., Cerutti, F., Monciotti, C., Pesavento, R., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2094-8 · Cited by 73
“In addition, KATP channel mutations are a prominent cause of transient neonatal diabetes mellitus (TNDM), a form of neonatal/infancy-onset diabetes that usually remits within 6 months of its onset [1, 2, 4].”
Role of molecular genetics in transforming diagnosis of diabetes mellitus
Molven, A., & Njølstad, P. R. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.123 · Cited by 71
Classification of diabetes mellitus and other categories of glucose intolerance
Magliano, D. J., Zimmet, P., & Shaw, J. E. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch1 · Cited by 77
Glucokinase (GCK) in diabetes: from molecular mechanisms to disease pathogenesis
Aqel, Y. W. A., Alnesf, A., Aigha, I. I., Islam, Z., Kolatkar, P. R., Teo, A. K. K., & Abdelalim, E. M. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00640-3 · Cited by 83
“This unique pathophysiology observed in individuals with MODY2 emphasize the importance of considering them as a separate genetic sub-group, markedly divergent from other MODY subtypes [115].”
BackgroundShaw-Smith, C. J., Flanagan, S. E., Patch, A., Grulich‐Henn, J., Habeb, A. M., Hussain, K., Pomahačová, R., Matyka, K. A., Abdullah, M., Hattersley, A. T., et al. (2012) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2012.00855.x · Cited by 61
“PNDM is both genetically and phenotypically heterogeneous (reviewed in reference (1)).”
BackgroundSelf-citationThe lessons of early-onset monogenic diabetes for the understanding of diabetes pathogenesis
Vaxillaire, M., Bonnefond, A., & Froguel, P. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.12.001 · Cited by 77
WFS1 mutations are frequent monogenic causes of juvenile-onset diabetes mellitus in Lebanon
Zalloua, P., Azar, S. T., Délepine, M., Makhoul, N. J., Blanc, H., Sanyoura, M., Lavergne, A., Stankov, K., Lemainque, A., Baz, P., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn304 · Cited by 61
Using genetics to prioritize diagnoses for rheumatology outpatients with inflammatory arthritis
Knevel, R., le Cessie, S., Terao, C., Slowikowski, K., Cui, J., Huizinga, T. W. J., Costenbader, K. H., Liao, K. P., Karlson, E. W., & Raychaudhuri, S. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1548 · Cited by 62
Steck, A. K., & Winter, W. E. (2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283488275 · Cited by 63
Epistasis of Transcriptomes Reveals Synergism between Transcriptional Activators Hnf1α and Hnf4α
Boj, S. F., Petrov, D., & Ferrer, J. P. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000970 · Cited by 60
“Despite transient differences in newborns, the diabetic phenotype in HNF1A and HNF4A patients shares many features, including similar disease progression curves, insulin secretory responses, and sensitivity to hypoglycemic drugs [18].”
Introduction to ISPAD Clinical Practice Consensus Guidelines 2014 Compendium
Acerini, C. L., Craig, M. E., de Beaufort, C. E., Maahs, D. M., & Hanås, R. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12182 · Cited by 64
Metadata
- Authors
- Murphy, R., Ellard, S., & Hattersley, A. T.
- Affiliations
- University of Exeter (GB)
- Corresponding author
- Hattersley, Andrew T
- Venue
- Nature Clinical Practice Endocrinology & Metabolism
- Published
- 2008-02-26
- Volume
- 4
- Issue
- 4
- Pages
- 200-213
- ISSN
- 1745-8366 (ISSN-L)
- 1745-8374
- OpenAlex
- W1996549380
- Semantic Scholar
- ca1487d43edc4a5abbe40904a2e6414a4534638e
- Cited by
- 502
- References
- 91
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 10 · 2023: 18 · 2022: 17 · 2021: 33 · 2020: 23 · 2019: 21 · 2018: 34 · 2017: 32 · 2016: 33 · 2015: 33 · 2014: 36 · 2013: 29 · 2012: 42
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Clinical Practice Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- Funders
- Wellcome Trust
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- monogenic diabetes, maturity-onset diabetes of the young, neonatal diabetes, molecular genetic classification, Kir6.2, SUR1, sulfonylurea therapy, glucokinase mutations, HNF1A, HNF4α, HNF1B, genetic counseling, insulin therapy
- MeSH terms
- Kcnj11 Channel, Diabetes Mellitus, Diagnosis, Differential, Female, Glucokinase, Humans, Infant, Newborn, Male, Mutation, Receptors, Drug, Potassium Channels, ATP-Binding Cassette Transporters, Potassium Channels, Inwardly Rectifying, Insulin-Secreting Cells, Hepatocyte Nuclear Factor 1-alpha, Hepatocyte Nuclear Factor 4, Sulfonylurea Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.